Targeting Oncogenic Transcriptional Networks in Neuroblastoma: From N-Myc to Epigenetic Drugs

Int J Mol Sci. 2021 Nov 28;22(23):12883. doi: 10.3390/ijms222312883.

Abstract

Neuroblastoma (NB) is one of the most frequently occurring neurogenic extracranial solid cancers in childhood and infancy. Over the years, many pieces of evidence suggested that NB development is controlled by gene expression dysregulation. These unleashed programs that outline NB cancer cells make them highly dependent on specific tuning of gene expression, which can act co-operatively to define the differentiation state, cell identity, and specialized functions. The peculiar regulation is mainly caused by genetic and epigenetic alterations, resulting in the dependency on a small set of key master transcriptional regulators as the convergence point of multiple signalling pathways. In this review, we provide a comprehensive blueprint of transcriptional regulation bearing NB initiation and progression, unveiling the complexity of novel oncogenic and tumour suppressive regulatory networks of this pathology. Furthermore, we underline the significance of multi-target therapies against these hallmarks, showing how novel approaches, together with chemotherapy, surgery, or radiotherapy, can have substantial antineoplastic effects, disrupting a wide variety of tumorigenic pathways through combinations of different treatments.

Keywords: CRC; GD2; HDACi; MYCN; epigenetic therapies; gene expression; neuroblastoma; oncogene; regulatory network; tumour suppressor.

Publication types

  • Review

MeSH terms

  • Animals
  • Chromosomal Instability
  • Epigenesis, Genetic
  • Gene Expression Regulation, Neoplastic*
  • Gene Regulatory Networks
  • Genes, myc*
  • Genetic Predisposition to Disease
  • Humans
  • Molecular Targeted Therapy*
  • Neuroblastoma / drug therapy
  • Neuroblastoma / genetics*